دورية أكاديمية
Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina.
| العنوان: | Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina. |
|---|---|
| المؤلفون: | Rodriguez PE; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina., Silva AP; Departamento Laboratorio de Diagnóstico y Referencia, Instituto Nacional de Epidemiología 'Dr. Juan H. Jara', Mar del Plata, Argentina., Miglietta EA; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina., Rall P; Instituto Nacional de Servicios Sociales para Jubilados y Pensionados (INSSJP-PAMI), Buenos Aires, Argentina., Pascuale CA; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina., Ballejo C; Departamento de Investigación Epidemiológica, Instituto Nacional de Epidemiología 'Dr. Juan H. Jara', Mar del Plata, Argentina., López Miranda L; Departamento Laboratorio de Diagnóstico y Referencia, Instituto Nacional de Epidemiología 'Dr. Juan H. Jara', Mar del Plata, Argentina., Ríos AS; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina., Ramis L; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina., Marro J; Departamento de Investigación Epidemiológica, Instituto Nacional de Epidemiología 'Dr. Juan H. Jara', Mar del Plata, Argentina., Poncet V; Departamento Laboratorio de Diagnóstico y Referencia, Instituto Nacional de Epidemiología 'Dr. Juan H. Jara', Mar del Plata, Argentina., Mazzitelli B; Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS)-CONICET, Facultad de Medicina Universidad de Buenos Aires (UBA), Buenos Aires, Argentina., Salvatori M; Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS)-CONICET, Facultad de Medicina Universidad de Buenos Aires (UBA), Buenos Aires, Argentina., Ceballos A; Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS)-CONICET, Facultad de Medicina Universidad de Buenos Aires (UBA), Buenos Aires, Argentina., Gonzalez Lopez Ledesma MM; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina., Ojeda DS; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina., Aguirre MF; Departamento de Investigación Epidemiológica, Instituto Nacional de Epidemiología 'Dr. Juan H. Jara', Mar del Plata, Argentina., Miragaya Y; Instituto Nacional de Servicios Sociales para Jubilados y Pensionados (INSSJP-PAMI), Buenos Aires, Argentina., Gamarnik AV; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina., Rossi AH; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina. |
| مؤلفون مشاركون: | Laboratorio SeVa Group, PAMI Group |
| المصدر: | Frontiers in immunology [Front Immunol] 2022 Sep 26; Vol. 13, pp. 992370. Date of Electronic Publication: 2022 Sep 26 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | COVID-19*/epidemiology , COVID-19*/prevention & control, Aged ; Aged, 80 and over ; Antibodies, Viral ; Argentina/epidemiology ; ChAdOx1 nCoV-19 ; Humans ; Immunoglobulin G ; Pandemics ; SARS-CoV-2 ; Vaccination |
| مستخلص: | The COVID-19 pandemic has particularly affected older adults residing in nursing homes, resulting in high rates of hospitalisation and death. Here, we evaluated the longitudinal humoral response and neutralising capacity in plasma samples of volunteers vaccinated with different platforms (Sputnik V, BBIBP-CorV, and AZD1222). A cohort of 851 participants, mean age 83 (60-103 years), from the province of Buenos Aires, Argentina were included. Sequential plasma samples were taken at different time points after vaccination. After completing the vaccination schedule, infection-naïve volunteers who received either Sputnik V or AZD1222 exhibited significantly higher specific anti-Spike IgG titers than those who received BBIBP-CorV. Strong correlation between anti-Spike IgG titers and neutralising activity levels was evidenced at all times studied (rho=0.7 a 0.9). Previous exposure to SARS-CoV-2 and age <80 years were both associated with higher specific antibody levels. No differences in neutralising capacity were observed for the infection-naïve participants in either gender or age group. Similar to anti-Spike IgG titers, neutralising capacity decreased 3 to 9-fold at 6 months after initial vaccination for all platforms. Neutralising capacity against Omicron was between 10-58 fold lower compared to ancestral B.1 for all vaccine platforms at 21 days post dose 2 and 180 days post dose 1. This work provides evidence about the humoral response and neutralising capacity elicited by vaccination of a vulnerable elderly population. This data could be useful for pandemic management in defining public health policies, highlighting the need to apply reinforcements after a complete vaccination schedule. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Rodriguez, Silva, Miglietta, Rall, Pascuale, Ballejo, López Miranda, Ríos, Ramis, Marro, Poncet, Mazzitelli, Salvatori, Ceballos, Gonzalez Lopez Ledesma, Ojeda, Aguirre, Miragaya, Gamarnik, Rossi, Laboratorio SeVa Group and PAMI Group.) |
| References: | Cell Rep Med. 2021 Aug 17;2(8):100359. (PMID: 34308389) BMC Public Health. 2022 Aug 20;22(1):1584. (PMID: 35987605) Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076) PLoS Pathog. 2021 Jan 14;17(1):e1009161. (PMID: 33444413) Front Immunol. 2022 Jan 27;13:829665. (PMID: 35154152) Lancet Infect Dis. 2022 May;22(5):589-590. (PMID: 35305316) Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089) Pulmonology. 2021 Sep-Oct;27(5):423-437. (PMID: 33867315) Front Immunol. 2020 Aug 07;11:1949. (PMID: 32849654) JAMA. 2021 May 11;325(18):1896-1898. (PMID: 33739374) Nature. 2021 Aug;596(7872):417-422. (PMID: 34192737) Lancet. 2021 Jul 17;398(10296):207-209. (PMID: 34197809) PLoS One. 2022 Feb 2;17(2):e0263468. (PMID: 35108321) Nephrol Dial Transplant. 2022 Sep 22;37(10):1868-1878. (PMID: 34788858) Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989) JAMA Netw Open. 2021 Oct 1;4(10):e2130800. (PMID: 34714342) Cell Rep Med. 2022 Aug 16;3(8):100706. (PMID: 35926505) Transplantation. 2022 Apr 1;106(4):821-834. (PMID: 34753894) J Clin Invest. 2021 Jun 15;131(12):. (PMID: 33956667) Vaccines (Basel). 2021 Sep 20;9(9):. (PMID: 34579284) Lancet Infect Dis. 2021 Jan;21(1):39-51. (PMID: 33069281) Lancet. 2021 Feb 20;397(10275):671-681. (PMID: 33545094) Lancet Infect Dis. 2022 Aug;22(8):1118-1119. (PMID: 35777383) Nat Microbiol. 2021 Sep;6(9):1140-1149. (PMID: 34290390) Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5. (PMID: 32735849) JAMA. 2020 May 12;323(18):1775-1776. (PMID: 32203977) Front Microbiol. 2022 Mar 10;13:816778. (PMID: 35359732) Lancet. 2022 Mar 26;399(10331):1254-1264. (PMID: 35303473) Lancet Microbe. 2022 Apr;3(4):e274-e283. (PMID: 35165669) Lancet. 2021 Dec 19;396(10267):1979-1993. (PMID: 33220855) Vaccines (Basel). 2021 Oct 21;9(11):. (PMID: 34835153) BMC Infect Dis. 2022 Jan 24;22(1):87. (PMID: 35073866) Science. 2022 Feb 11;375(6581):678-680. (PMID: 35040667) Ageing Res Rev. 2021 Jan;65:101205. (PMID: 33137510) mBio. 2022 Jan 25;:e0344221. (PMID: 35073758) Eur J Heart Fail. 2021 Nov;23(11):1806-1818. (PMID: 34612556) Ann Med. 2022 Dec;54(1):524-540. (PMID: 35132910) Sci Transl Med. 2022 Feb 09;14(631):eabi8961. (PMID: 34874183) J Allergy Clin Immunol. 2020 May;145(5):1309-1321. (PMID: 32386655) |
| معلومات مُعتمدة: | U19 AI168631 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Investigator: DRR García; MG Bialer; MJ de Leone; NB Rasetto; SD Wenker; L Bianchimano; MST Cienfuegos; CE Hernando; DA Careno; C Garcia; MV Alcón; DS Centurión; CR Velázquez; NI Aztorga; R Solazzi; FM Bacigaluppe; MS Fernández; H Salaya; E Perez Keywords: AZD1222; BBIBP-CorV; Omicron; SARS-CoV-2; Sputnik-V; aging adults; anti-spike IgG; neutralising antibodies |
| المشرفين على المادة: | 0 (Antibodies, Viral) 0 (Immunoglobulin G) B5S3K2V0G8 (ChAdOx1 nCoV-19) |
| تواريخ الأحداث: | Date Created: 20221013 Date Completed: 20221014 Latest Revision: 20221230 |
| رمز التحديث: | 20221230 |
| مُعرف محوري في PubMed: | PMC9549602 |
| DOI: | 10.3389/fimmu.2022.992370 |
| PMID: | 36225925 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2022.992370 |